Jeff Jones
Stock Analyst at Oppenheimer
(4.70)
# 769
Out of 4,646 analysts
279
Total ratings
46.2%
Success rate
20.5%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACRV Acrivon Therapeutics | Maintained: Buy | $8 | $1.79 | +346.93% | 2 | Aug 13, 2026 | |
| AVBP ArriVent BioPharma | Maintained: Buy | $50 | $30.10 | +66.11% | 9 | Aug 13, 2026 | |
| CATX Perspective Therapeutics | Reiterated: Buy | $13 | $3.18 | +308.81% | 32 | Aug 11, 2026 | |
| BCYC Bicycle Therapeutics | Initiated Coverage: Buy | $11 | $4.01 | +174.66% | 1 | Jul 31, 2026 | |
| ALMS Alumis | Reiterated: Buy | $55 | $25.26 | +117.74% | 14 | Jul 15, 2026 | |
| ODTX Odyssey Therapeutics | Reiterated: Buy | $40 | $21.13 | +89.30% | 2 | Jun 18, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Reiterated: Buy | $54 → $52 | $10.02 | +418.96% | 23 | Jun 17, 2026 | |
| AAPG Ascentage Pharma Group International | Initiated Coverage: Buy | $45 | $18.98 | +137.14% | 1 | Jun 15, 2026 | |
| MDWD MediWound | Maintained: Buy | $34 → $32 | $13.59 | +135.55% | 5 | May 28, 2026 | |
| CRVS Corvus Pharmaceuticals | Reiterated: Buy | $33 | $15.07 | +118.98% | 17 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25 | $1.90 | +1,215.79% | 22 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $62 → $66 | $29.39 | +124.57% | 8 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $5 | $1.24 | +304.86% | 16 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $34.49 | +44.97% | 10 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $5.92 | +68.92% | 2 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 → $7 | $4.74 | +47.68% | 4 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $41 → $40 | $11.90 | +236.13% | 9 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $86 | $34.12 | +152.05% | 7 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.54 | - | 20 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $120 | $114.19 | +5.09% | 12 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $17 → $16 | $5.70 | +180.70% | 4 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $19 → $20 | $6.44 | n/a | 2 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $1.10 | n/a | 22 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.46 | n/a | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $6.07 | n/a | 7 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $0.557 | n/a | 5 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $1.03 | n/a | 4 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $0.889 | n/a | 4 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $3.17 | n/a | 3 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.00001 | n/a | 2 | Jul 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.001 | n/a | 1 | Sep 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $37 | $54.85 | n/a | 1 | Jun 22, 2021 |
Acrivon Therapeutics
Aug 13, 2026
Maintained: Buy
Price Target: $8
Current: $1.79
Upside: +346.93%
ArriVent BioPharma
Aug 13, 2026
Maintained: Buy
Price Target: $50
Current: $30.10
Upside: +66.11%
Perspective Therapeutics
Aug 11, 2026
Reiterated: Buy
Price Target: $13
Current: $3.18
Upside: +308.81%
Bicycle Therapeutics
Jul 31, 2026
Initiated Coverage: Buy
Price Target: $11
Current: $4.01
Upside: +174.66%
Alumis
Jul 15, 2026
Reiterated: Buy
Price Target: $55
Current: $25.26
Upside: +117.74%
Odyssey Therapeutics
Jun 18, 2026
Reiterated: Buy
Price Target: $40
Current: $21.13
Upside: +89.30%
Corbus Pharmaceuticals Holdings
Jun 17, 2026
Reiterated: Buy
Price Target: $54 → $52
Current: $10.02
Upside: +418.96%
Ascentage Pharma Group International
Jun 15, 2026
Initiated Coverage: Buy
Price Target: $45
Current: $18.98
Upside: +137.14%
MediWound
May 28, 2026
Maintained: Buy
Price Target: $34 → $32
Current: $13.59
Upside: +135.55%
Corvus Pharmaceuticals
May 15, 2026
Reiterated: Buy
Price Target: $33
Current: $15.07
Upside: +118.98%
May 15, 2026
Maintained: Buy
Price Target: $25
Current: $1.90
Upside: +1,215.79%
May 15, 2026
Reiterated: Buy
Price Target: $62 → $66
Current: $29.39
Upside: +124.57%
May 13, 2026
Maintained: Buy
Price Target: $6 → $5
Current: $1.24
Upside: +304.86%
May 13, 2026
Reiterated: Buy
Price Target: $50
Current: $34.49
Upside: +44.97%
May 8, 2026
Reiterated: Buy
Price Target: $10
Current: $5.92
Upside: +68.92%
May 8, 2026
Reiterated: Buy
Price Target: $6 → $7
Current: $4.74
Upside: +47.68%
May 8, 2026
Maintained: Buy
Price Target: $41 → $40
Current: $11.90
Upside: +236.13%
Apr 20, 2026
Maintained: Buy
Price Target: $86
Current: $34.12
Upside: +152.05%
Mar 2, 2026
Rated: Hold
Price Target: n/a
Current: $2.54
Upside: -
Feb 27, 2026
Reiterated: Buy
Price Target: $120
Current: $114.19
Upside: +5.09%
Aug 15, 2025
Maintained: Buy
Price Target: $17 → $16
Current: $5.70
Upside: +180.70%
Aug 14, 2025
Maintained: Buy
Price Target: $19 → $20
Current: $6.44
Upside: n/a
Aug 8, 2025
Maintained: Hold
Price Target: n/a
Current: $1.10
Upside: n/a
Oct 29, 2024
Rated: Hold
Price Target: n/a
Current: $4.46
Upside: n/a
Aug 14, 2024
Maintained: Hold
Price Target: n/a
Current: $6.07
Upside: n/a
Nov 30, 2023
Maintained: Buy
Price Target: n/a
Current: $0.557
Upside: n/a
Nov 10, 2023
Maintained: Hold
Price Target: n/a
Current: $1.03
Upside: n/a
Nov 7, 2023
Maintained: Buy
Price Target: n/a
Current: $0.889
Upside: n/a
Apr 28, 2023
Rated: Buy
Price Target: n/a
Current: $3.17
Upside: n/a
Jul 20, 2022
Downgraded: Hold
Price Target: n/a
Current: $0.00001
Upside: n/a
Sep 30, 2021
Reiterated: Hold
Price Target: n/a
Current: $0.001
Upside: n/a
Jun 22, 2021
Maintained: Buy
Price Target: $37
Current: $54.85
Upside: n/a